The stock of Gemphire Therapeutics Inc (NASDAQ:GEMP) is a huge mover today! The stock decreased 3.36% or $0.38 on September 30, hitting $10.92. About 63,002 shares traded hands or 30.13% up from the average. Gemphire Therapeutics Inc (NASDAQ:GEMP) has risen 6.00% since September 1, 2016 and is uptrending. It has underperformed by 4.42% the S&P500.
The move comes after 6 months negative chart setup for the $92.55 million company. It was reported on Oct, 1 by Barchart.com. We have $9.61 PT which if reached, will make NASDAQ:GEMP worth $11.11 million less.
Gemphire Therapeutics Inc (NASDAQ:GEMP) Ratings Coverage
Out of 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Gemphire Therapeutics has been the topic of 3 analyst reports since August 30, 2016 according to StockzIntelligence Inc. The company was initiated on Tuesday, August 30 by Canaccord Genuity. As per Tuesday, August 30, the company rating was initiated by Jefferies. The firm earned “Outperform” rating on Tuesday, August 30 by RBC Capital Markets.
According to Zacks Investment Research, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan.”
More notable recent Gemphire Therapeutics Inc (NASDAQ:GEMP) news were published by: Globenewswire.com which released: “Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial …” on September 26, 2016, also Crainsdetroit.com with their article: “Gemphire Therapeutics sets IPO for Thursday” published on June 20, 2016, Globenewswire.com published: “Gemphire Therapeutics Announces Pricing of Initial Public Offering” on August 04, 2016. More interesting news about Gemphire Therapeutics Inc (NASDAQ:GEMP) were released by: Crainsdetroit.com and their article: “Gemphire Therapeutics files for $60 million IPO” published on April 25, 2016 as well as Benzinga.com‘s news article titled: “Gemphire Therapeutics’ Oral Cholesterol Drug Could Have $2.8 Billion Potential …” with publication date: August 30, 2016.
GEMP Company Profile
Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing therapies for the treatment of dyslipidemia. The Firm is developing its product candidate Gemcabene (CI-1027), once-daily, oral therapy, for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. The Firm is developing Gemcabene for familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease (ASCVD) and severe hypertriglyceridemia (SHTG).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.